Log in

NASDAQ:BLRX - BIOLINERX LTD/S Stock Price, Forecast & News

$2.09
+0.03 (+1.46 %)
(As of 02/19/2020 02:05 AM ET)
Today's Range
$2.00
Now: $2.09
$2.12
50-Day Range
$2.04
MA: $2.34
$2.60
52-Week Range
$1.55
Now: $2.09
$7.46
Volume38,100 shs
Average Volume82,259 shs
Market Capitalization$15.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-2548-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.82 per share

Profitability

Net Income$-22,960,000.00

Miscellaneous

Employees51
Market Cap$15.63 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.


BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions

What is BIOLINERX LTD/S's stock symbol?

BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."

How were BIOLINERX LTD/S's earnings last quarter?

BIOLINERX LTD/S (NASDAQ:BLRX) released its earnings results on Thursday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.07). View BIOLINERX LTD/S's Earnings History.

When is BIOLINERX LTD/S's next earnings date?

BIOLINERX LTD/S is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for BIOLINERX LTD/S.

What price target have analysts set for BLRX?

3 analysts have issued 12 month target prices for BIOLINERX LTD/S's stock. Their forecasts range from $3.00 to $10.00. On average, they expect BIOLINERX LTD/S's share price to reach $6.50 in the next year. This suggests a possible upside of 211.0% from the stock's current price. View Analyst Price Targets for BIOLINERX LTD/S.

What is the consensus analysts' recommendation for BIOLINERX LTD/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX LTD/S.

Has BIOLINERX LTD/S been receiving favorable news coverage?

Media stories about BLRX stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BIOLINERX LTD/S earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View News Stories for BIOLINERX LTD/S.

Who are some of BIOLINERX LTD/S's key competitors?

What other stocks do shareholders of BIOLINERX LTD/S own?

Who are BIOLINERX LTD/S's key executives?

BIOLINERX LTD/S's management team includes the folowing people:
  • Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)
  • Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)
  • Dr. Ella Sorani, VP R&D (Age 51)
  • Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67)

Who are BIOLINERX LTD/S's major shareholders?

BIOLINERX LTD/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Senvest Management LLC (8.41%) and Cutter & CO Brokerage Inc. (0.16%).

Which institutional investors are buying BIOLINERX LTD/S stock?

BLRX stock was purchased by a variety of institutional investors in the last quarter, including Senvest Management LLC and Cutter & CO Brokerage Inc..

How do I buy shares of BIOLINERX LTD/S?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIOLINERX LTD/S's stock price today?

One share of BLRX stock can currently be purchased for approximately $2.09.

How big of a company is BIOLINERX LTD/S?

BIOLINERX LTD/S has a market capitalization of $15.63 million. The biotechnology company earns $-22,960,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe.View Additional Information About BIOLINERX LTD/S.

What is BIOLINERX LTD/S's official website?

The official website for BIOLINERX LTD/S is http://www.biolinerx.com/.

How can I contact BIOLINERX LTD/S?

BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]


MarketBeat Community Rating for BIOLINERX LTD/S (NASDAQ BLRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  464 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  749
MarketBeat's community ratings are surveys of what our community members think about BIOLINERX LTD/S and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel